If such a trial is in fact being planned, it must be either: a) a trial for the ex-US market; or b) a bioequivalence trial (as opposed to a safety and efficacy trial).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”